2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF):

  • 22 January 2025:                      Silent period                       
  • 19 February 2025:                    Annual report 2024             
  • 13 March 2025 at 4.00 p.m.:     Annual General Meeting
to be held at ALK

Bøge Allé 1

2970 Hørsholm, Denmark

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

Written requests to have specific business

transacted at the AGM will be included in the

agenda if received by the company on

29 January 2025 at the latest

(may be emailed to [email protected])

  • 8 April 2025:                             Silent period                       
  • 6 May 2025:                             Three-month interim report (Q1) 2025             
  • 24 July 2025:                            Silent period                       
  • 21 August 2025:                       Six-month interim report (Q2) 2025                 
  • 16 October 2025:                      Silent period                       
  • 13 November 2025:                  Nine-month interim report (Q3) 2025              
ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Maiken Riise Andersen, tel. +45 5054 1434

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment